Nicola Della Valle
Overview
Explore the profile of Nicola Della Valle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stoppino L, Piscone S, Quarta Colosso O, Saccone S, Milillo P, Della Valle N, et al.
J Imaging
. 2024 Nov;
10(11).
PMID: 39590747
A retrospective analysis was conducted to investigate how a bright luminal sign on high b-value diffusion-weighted imaging (DWI) could be considered as a new biomarker for identifying fibrotic strictures in...
2.
Tursi A, Mocci G, Scaldaferri F, Napolitano D, Maresca R, Pugliese D, et al.
Expert Opin Biol Ther
. 2024 Jan;
24(1-2):101-109.
PMID: 38250818
Background: Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist recently approved for treating ulcerative colitis (UC) but with limited real-world data. Therefore, we evaluated the effectiveness and safety of UST in...
3.
Tursi A, Mocci G, Cingolani L, Savarino E, Pica R, Cocco A, et al.
Expert Opin Pharmacother
. 2023 Jun;
24(14):1649-1656.
PMID: 37358928
Background: Data regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF's RW efficacy and safety in Italian UC...
4.
Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M, et al.
Expert Opin Biol Ther
. 2023 Feb;
23(3):293-304.
PMID: 36843568
Background: Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ. Research...
5.
Tursi A, Mocci G, Cuomo A, Ferronato A, Elisei W, Picchio M, et al.
J Gastrointestin Liver Dis
. 2022 Dec;
31(4):411-416.
PMID: 36535057
Background And Aims: Adalimumab (ADA) biosimilars have been included into the therapeutic armamentarium of inflammatory bowel disease (IBD); however, comparative data on the efficacy and safety of the different ADA...
6.
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco M, Colucci R, et al.
Inflamm Bowel Dis
. 2022 May;
29(3):376-383.
PMID: 35579320
Background: Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for the treatment of a greater number of patients for their reduced cost than the...
7.
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco M, Colucci R, et al.
Expert Opin Biol Ther
. 2021 Dec;
22(2):313-320.
PMID: 34904510
Background: To compare the performances of Infliximab (IFX) biosimilar CT-P13 and SB2 in the treatment of Inflammatory Bowel Diseases (IBD) outpatients in Italy. Research Design And Methods: Three hundred and...
8.
Tursi A, Mocci G, Elisei W, Allegretta L, Colucci R, Della Valle N, et al.
J Gastrointestin Liver Dis
. 2021 Nov;
30(4):456-461.
PMID: 34812437
Background And Aims: Several studies have found Golimumab (GOL) effective and safe in the short-term treatment of ulcerative colitis (UC), but few long-term data are currently available from real world....
9.
Tursi A, Mocci G, Faggiani R, Allegretta L, Della Valle N, Forti G, et al.
Ann Gastroenterol
. 2019 Jul;
32(4):392-399.
PMID: 31263362
Background: The purpose of this study was to assess the efficacy and safety of biosimilar infliximab (IFX) CT-P13 in treating outpatients with inflammatory bowel disease (IBD) in Italian primary gastroenterology...
10.
Tursi A, Mocci G, Faggiani R, Allegretta L, Della Valle N, De Medici A, et al.
Eur J Intern Med
. 2019 Jun;
66:85-91.
PMID: 31208827
Background: Italian data currently available in managing ulcerative colitis (UC) and Crohn's disease (CD) patients with vedolizumab (VDZ) are coming just from secondary and tertiary centers. The present study aimed...